Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for the treatment of moderate to severe acute pain in adults. Developed by Vertex Pharmaceuticals, Journavx represents a novel approach to pain management, targeting sodium channels in the peripheral nervous system to block pain signals ...